Glycation on lysine side chains of recombinant monoclonal antibodies
(mAb) is a well known phenomenon in manufacturing processes of
biopharmaceuticals that potentially alter the efficacy of the
therapeutic protein. Previously, we reported a method to quantify the
level of glycation formation directly from cell culture supernatants
using boronate affinity chromatography (BAC). In this study, we report
kinetic studies of glycation formation of the model protein Adalimumab,
related to glucose and non-glycated protein in six CHO fed batch
cultivations. An in-vivo model was demonstrated from glycation kinetic
studies that is capable of estimating the reaction rate constant in
static and dynamic bioprocesses, respectively. As anticipated, pseudo
first order reactions with respect to present glucose concentration or
non-glycated mAb were not sufficient to describe the glycation formation
during the bioprocesses. However, second order reactions did not reveal
linear relationship of glycated mAb to the product of glucose and
non-glycated mAb, suggesting a reconsideration of kinetic equation. With
the introduction of a constraint using only the newly formed product,
i.e., the nascent protein, the second-order reaction was successfully
implemented. These results show that the process knowledge derived from
dynamic can be transferred to static experiments and vice versa. Hence,
intensified DoE can be an applicable and useful tool in product quality
studies in cell culture processes.